David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Ezio Di Nucci
Jack Alan Reynolds
Learn more about PhilPapers
Philosophy, Ethics, and Humanities in Medicine 6 (1):8- (2011)
We reply to the Ioannidis's paper "Effectiveness of antidepressants; an evidence based myth constructed from a thousand controlled trials." We disagree that antidepressants have no greater efficacy than placebo. We present the efficacy from hundreds of trials in terms of the percentage of patients with a substantial clinical response (a 50% improvement or more symptomatic reduction). This meta-analysis finds that 42-70% of depressed patients improve with drug and 21%-39% improve with placebo. The response benefit of antidepressant treatment is 33%-11% greater than placebo. Ioannidis argues that it would be vanishingly smaller because systematic biasing in these clinical trials would reduce the drug-placebo difference to zero. Ioannidis' argument that antidepressants have no benefit is eroded by his failures of logic because he does not present any evidence that there are a large number of studies where placebo is substantially more effective than drug. (To reduce to zero, one would also have to show that some of the unpublished studies find placebo better than drug and have substantial systematic or methodological bias). We also present the empirical evidence showing that these methodological concerns generally have the opposite effect of what Ioannidis argues, supporting our contention that the measured efficacy of antidepressants likely underestimates true efficacy.Our most important criticism is Ioannidis’ basic underlying argument about antidepressants that if the existing evidence is imperfect and methods can be criticized, then this proves that antidepressant are not efficacious. He presents no credible evidence that antidepressants have zero effect size. Valid arguments can point out difficulties with the data but do not prove that a given drug had no efficacy. Indeed better evidence might prove it was more efficacious that originally found.We find no empirical or ethical reason why psychiatrists should not try to help depressed patients with drugs and/or with psychotherapeutic/behavioral treatments given evidence of efficacy even though our treatment knowledge has limitations. The immense suffering of patients with major depression leads to ethical, moral, professional and legal obligations to treat patients with the best available tools at our disposal, while diligently and actively monitoring for adverse effects and actively revising treatment components as necessary
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
John PA Ioannidis (2008). Effectiveness of Antidepressants: An Evidence Myth Constructed From a Thousand Randomized Trials? [REVIEW] Philosophy, Ethics, and Humanities in Medicine 3 (1):14.
Stanisław Pużyński (2004). Placebo in the Investigation of Psychotropic Drugs, Especially Antidepressants. Science and Engineering Ethics 10 (1):135-142.
Thomas R. Weihrauch (2004). Placebo Treatment is Effective Differently in Different Diseases — but is It Also Harmless? A Brief Synopsis. Science and Engineering Ethics 10 (1):151-155.
Jacek Spławiński, Jerzy Kuźniar, Krzysztof Filipiak & Waldemar Zieliński (2006). Evaluation of Drug Toxicity in Clinical Trials. Science and Engineering Ethics 12 (1):139-145.
Thomas C. Jones (2005). A Call to Restructure the Drug Development Process: Government Over-Regulation and Non-Innovative Late Stage (Phase III) Clinical Trials Are Major Obstacles to Advances in Health Care. Science and Engineering Ethics 11 (4):575-587.
Jacek Spławiński & Jerzy Kuźniar (2004). Clinical Trials: Active Control Vs Placebo — What is Ethical? Science and Engineering Ethics 10 (1):73-79.
Paul Biegler (2010). Autonomy and Ethical Treatment in Depression. Bioethics 24 (4):179-189.
Dimitris Repantis, Peter Schlattmann, Oona Laisney & Isabella Heuser (2009). Antidepressants for Neuroenhancement in Healthy Individuals: A Systematic Review. [REVIEW] Poiesis and Praxis 6 (3-4):139-174.
Franklin G. Miller & Howard Brody (2002). What Makes Placebo-Controlled Trials Unethical? American Journal of Bioethics 2 (2):3 – 9.
Raúl de la Fuente-Fernández & A. Jon Stoessl (2004). The Biochemical Bases of the Placebo Effect. Science and Engineering Ethics 10 (1):143-150.
Jeremy Sugarman (2004). Using Empirical Data to Inform the Ethical Evaluation of Placebo Controlled Trials. Science and Engineering Ethics 10 (1):29-35.
Jeremy Howick, Against a Priori Judgements of Bad Methodology: Questioning Double-Blinding as a Universal Methodological Virtue of Clinical Trials.
Bozidar Vrhovac (2004). Placebo and the Helsinki Declaration — What to Do? Science and Engineering Ethics 10 (1):81-93.
Zbigniew Szawarski (2004). The Concept of Placebo. Science and Engineering Ethics 10 (1):57-64.
Added to index2011-05-11
Total downloads25 ( #146,796 of 1,789,801 )
Recent downloads (6 months)2 ( #315,596 of 1,789,801 )
How can I increase my downloads?